Dr. Noureddin is the founding Director of Cedars-Sinai’s Fatty Liver Program in Los Angeles, California.
His research focuses on the underlying mechanisms of non- alcoholic fatty
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new imaging modalities, non-invasive
biomarkers, and exploring new treatments. He has conducted several original studies that have been featured
in publications in Gastroenterology, Journal of Hepatology, Gut, Hepatology, The American Journal of
Gastroenterology, and many others. The Fatty Liver Program at Cedars- Sinai is conducting a number of
breakthrough studies and clinical trials targeting new therapies in patients NAFLD and NASH, including those
with advanced fibrosis and cirrhosis.